Ranibizumab treatment of retinal vein occlusion

References

• Klein R, Klein BEK, Lee KE, Cruickshanks KJ, Gangnon RE. Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am. J.Ophthalmol. 142, 539–549 (2006).
   PubMed Web of Science ®Google Scholar
• Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch. Ophthalmol. 126(4), 513–518 (2008).
   PubMed Web of Science ®Google Scholar
• Rogers S, McIntosh RL, Cheung N et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(2), 313–319.e1 (2010).
   PubMed Web of Science ®Google Scholar
• Michaelson IC. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans. Ophthalmol. Soc. UK 68, 137–180 (1948).
   Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18(1), 4–25 (1997).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26(8), 859–870 (2006).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331(22), 1480–1487 (1994).
   PubMed Web of Science ®Google Scholar
• Adamis AP, Miller JW, Bernal MT et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118(4), 445–450 (1994).
   PubMed Web of Science ®Google Scholar
• Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br. J. Ophthalmol. 80(3), 241–245 (1996).
   PubMed Web of Science ®Google Scholar
• Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105(3), 412–416 (1998).
   PubMed Web of Science ®Google Scholar
• Noma H, Funatsu H, Yamasaki M et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am. J. Ophthalmol. 140(2), 256–261 (2005).
   PubMed Web of Science ®Google Scholar
• Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am. J. Ophthalmol. 122(3), 393–403 (1996).
   PubMed Web of Science ®Google Scholar
• Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am. J. Ophthalmol. 98, 271–282 (1984).
   PubMed Web of Science ®Google Scholar
• Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 102, 1425–1433 (1995).
   PubMed Web of Science ®Google Scholar
• The SCORE Study Research group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch. Ophthalmol. 127(9), 1101–1114 (2009).
   PubMedGoogle Scholar
• The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion. The standard care vs. corticosteroid for retinal vein occlusion (SCORE) study report 6. Arch. Ophthalmol. 127(9), 1115–1128 (2009).
   PubMed Web of Science ®Google Scholar
• HallerJA, BandelloF, BelfortR Jr et al.; the Ozurdex GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6), 1134–1146 (2010).
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Heier JS, Feiner L et al.; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 117(6), 1102–1112.e1 (2010).
   PubMed Web of Science ®Google Scholar
• Brown DM, Campochiaro PA, Singh RP et al.; the CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 117(6), 1124–1133.e1 (2010).
   PubMed Web of Science ®Google Scholar
• Boyer D, Heier J, Brown DM et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the Phase 3 COPERNICUS study. Ophthalmology 119(5), 1024–1032 (2012).
   PubMed Web of Science ®Google Scholar
• Shahar J, Avery RL, Heilweil G et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26(3), 262–269 (2006).
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46(2), 726–733 (2005).
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114(12), 2179–2182 (2007).
   PubMed Web of Science ®Google Scholar
• Heier JS, Campochiaro PA, Yau L et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119(4), 802–809 (2012).
   PubMed Web of Science ®Google Scholar
• Brown DM, Campochiaro PA, Bhisitkul RB et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a Phase III study. Ophthalmology 118(8), 1594–1602 (2011).
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Awh CC et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a Phase III study. Ophthalmology 118(10), 2041–2049 (2011).
   PubMed Web of Science ®Google Scholar
• McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 31(4), 654–661 (2011).
   PubMed Web of Science ®Google Scholar
• Wehrli SJ, Tawse K, Levin MH, Zaidi A, Pistilli M, Brucker AJ. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina 32(7), 1295–1301 (2012).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116(9), 1731–1739 (2009).
   PubMed Web of Science ®Google Scholar